Between 20% and 50% of hospital inpatients are malnourished. Most are never formally diagnosed. That single, stubborn failure in clinical detection is what gave Healthleap its original reason to exist — and it turns out the problem runs much deeper than nutrition alone.
Healthleap, a startup founded in South Africa in 2022 by siblings Jemima and Josiah Meyer, has raised $38 million in total funding, TechCrunch has exclusively learned. The financing includes an $8 million seed round co-led by Sequoia Capital and First Round Capital, and a $30 million Series A led by Hummingbird Ventures. The company is not disclosing its valuation.
The company started with a clinical nutrition tool Jemima had built for dietitians, but later shifted toward something broader: a general-purpose platform that screens admitted patients for conditions that routinely slip through the cracks, including malnutrition, delirium, aspiration pneumonia, pressure ulcers, and readmission risk for congestive heart failure.
What the platform actually does
The core insight behind Healthleap is that a hospital chart contains two very different kinds of information. Structured data — labs, vitals, weights — sits in clean, queryable fields. But some of the most clinically meaningful signals live in free-text notes written by nurses, physicians, and dietitians: mentions of poor appetite, recent weight loss, difficulty swallowing, or confusion. Those notes are rarely analyzed systematically.
Healthleap connects to a hospital’s electronic health record system and uses language models to extract both affirmative and negated mentions of clinical concepts from written notes. That information feeds into risk models alongside structured data to surface patients who may warrant a closer look. The software does not diagnose — it flags for review.
“Each night, we analyze every adult inpatient’s record: lab results, vital signs, weights, medications, diet orders, diagnoses, clinicians’ notes, and more,” CEO Josiah Meyer told TechCrunch. “Each morning, we write a risk score into the care team’s existing workflow with a dashboard that holds additional information about the patients’ trends.”
Who’s using it and what it’s returning
The startup has grown from three hospital partners to more than 50 over the past year. Current customers include Penn Medicine, Cedars-Sinai, Intermountain Health, Houston Methodist, and Emory Healthcare. Revenue has grown more than 10x in the same period, though Meyer did not share specific figures.
Contracts run three years and are priced by licensed bed count, with an outcome-based component tied to validated financial returns. Meyer says every customer to date has seen at least a 5x hard return on investment, and some have seen more than 20x annually.
At the Hospital of the University of Pennsylvania, Healthleap says its malnutrition program produced $23.8 million in annualized financial impact. Of that, $6.3 million came from additional reimbursement and $17.5 million from shorter hospital stays. Those are figures the hospital finance team validated and attributed directly to the program — not projections.
Why malnutrition was the right place to start
Malnutrition is underdiagnosed, clinically consequential, and poorly captured in structured data. Studies have linked it to longer stays, impaired wound healing, higher infection rates, and increased mortality. So it’s an obvious test case for a platform built on detecting what charts miss. But it’s also a condition where intervention is relatively straightforward once a patient is identified — which makes the return on detection faster and easier to measure.
That measurability matters. Hospitals are under serious financial pressure, and a product that a finance team can independently validate is a much easier sell than one that relies on clinical intuition alone.
What comes next
Healthleap plans to use the new capital for engineering, product development, sales, and customer success. The longer-term ambition is to cover more than 40 major health conditions and extend the platform beyond the inpatient setting into outpatient care and the home.
The programs for aspiration pneumonia, pressure ulcers, and heart failure readmission are still in clinical validation. But the infrastructure — nightly chart analysis, NLP-based concept extraction, risk scoring within existing clinical workflows — is already running at scale. And the conditions Healthleap is going after next are no less undertreated than the one it started with.